Literature DB >> 20538883

Lactic acidemia in the pathogenesis of mice carrying mitochondrial DNA with a deletion.

Emi Ogasawara1, Kazuto Nakada, Jun-Ichi Hayashi.   

Abstract

Lactic acidemia is one manifestation of the mitochondrial diseases caused by pathogenic mutant mitochondrial DNA (mtDNA). However, little is known about its chronic effects in the progression of mitochondrial disease phenotypes. To obtain experimental evidence on this point, we used trans-mitochondrial model mice (mito-mice) heteroplasmic for wild-type and deleted mtDNA (DeltamtDNA). Mito-mice carrying predominantly DeltamtDNA showed mitochondrial respiration defects and the resultant disease phenotypes, including lactic acidemia; they also showed a decrease in mitochondrial biogenesis regulated by the peroxisome proliferative activated receptor gamma, coactivator 1 alpha (PGC1alpha)-mediated pathway, such as the expression of mitochondrial transcription factor A and mtDNA-encoded gene products and the control of mtDNA content. When the accelerated lactate production of these mito-mice was pharmacologically inhibited by sodium dichloroacetate (DCA), the decrease in mitochondrial biogenesis improved, thus leading to the relaxation of mitochondrial respiration defects and extension of life span. These results showed that chronic overproduction of lactate caused by metabolic adaptation in mitochondrial diseases further deconditioned mitochondrial function. Mitochondrial respiration defects in mitochondrial diseases are therefore induced not only directly by the presence of mutant mtDNA, but also by the chronic lactic acidemia. Our in vivo study also suggested that inhibition of chronic lactic acidemia is a potential strategy for treating some mitochondrial diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538883     DOI: 10.1093/hmg/ddq228

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  6 in total

1.  Acquired Expression of Mutant Mitofusin 2 Causes Progressive Neurodegeneration and Abnormal Behavior.

Authors:  Kaori Ishikawa; Satoshi Yamamoto; Satoko Hattori; Naoya Nishimura; Haruna Tani; Takayuki Mito; Hirokazu Matsumoto; Tsuyoshi Miyakawa; Kazuto Nakada
Journal:  J Neurosci       Date:  2019-01-03       Impact factor: 6.167

2.  Mitochondrial DNA with a large-scale deletion causes two distinct mitochondrial disease phenotypes in mice.

Authors:  Shun Katada; Takayuki Mito; Emi Ogasawara; Jun-Ichi Hayashi; Kazuto Nakada
Journal:  G3 (Bethesda)       Date:  2013-09-04       Impact factor: 3.154

3.  Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis.

Authors:  Rosa Ferriero; Giuseppe Manco; Eleonora Lamantea; Edoardo Nusco; Maria I Ferrante; Paolo Sordino; Peter W Stacpoole; Brendan Lee; Massimo Zeviani; Nicola Brunetti-Pierri
Journal:  Sci Transl Med       Date:  2013-03-06       Impact factor: 17.956

4.  Human mitochondrial disease-like symptoms caused by a reduced tRNA aminoacylation activity in flies.

Authors:  Tanit Guitart; Daria Picchioni; David Piñeyro; Lluís Ribas de Pouplana
Journal:  Nucleic Acids Res       Date:  2013-05-15       Impact factor: 16.971

5.  Loss of UCP2 attenuates mitochondrial dysfunction without altering ROS production and uncoupling activity.

Authors:  Alexandra Kukat; Sukru Anil Dogan; Daniel Edgar; Arnaud Mourier; Christoph Jacoby; Priyanka Maiti; Jan Mauer; Christina Becker; Katharina Senft; Rolf Wibom; Alexei P Kudin; Kjell Hultenby; Ulrich Flögel; Stephan Rosenkranz; Daniel Ricquier; Wolfram S Kunz; Aleksandra Trifunovic
Journal:  PLoS Genet       Date:  2014-06-19       Impact factor: 5.917

6.  Mitochondrial DNA deletion-dependent podocyte injuries in Mito-miceΔ, a murine model of mitochondrial disease.

Authors:  Shuzo Kaneko; Joichi Usui; Masahiro Hagiwara; Tatsuya Shimizu; Ryota Ishii; Mayumi Takahashi-Kobayashi; Mikiko Kageyama; Kazuto Nakada; Jun-Ichi Hayashi; Kunihiro Yamagata
Journal:  Exp Anim       Date:  2021-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.